Catalina Research Institute
Catalina Research Institute
Montclair, California, United States7 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 3 | 2026-10-05 | NCT07684235 | |
| "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06564818 | |
| An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1) | Stress Disorders, Traumatic, acute stress disorder, post-traumatic stress disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-09-17 | NCT07456696 | |
| Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 3 | 2026-09-17 | NCT06858839 | |
| An Evaluation of the Long-Term Safety and Efficacy of TSND-201 for the Treatment of PTSD | Stress Disorders, Traumatic, acute stress disorder, post-traumatic stress disorder, psychiatric disorder | Enrolling by invitation | Phase 3 | 2026-09-04 | NCT07670702 | |
| A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH) | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Recruiting | Phase 2 | 2026-05-18 | NCT07491458 | |
| Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Active, not recruiting | Phase 2 | 2025-04-18 | NCT05979779 |